drugset
drugset / Trial / NCT04748471

Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)

NCT04748471 ↗

Phase 2 Unknown 180 enrolled Assistance Publique - Hôpitaux de Paris Institut National de la Santé Et de la Recherche Médicale, France · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study aims to evaluate the immunogenicity of Moderna mRNA-1273 vaccine in volunteers aged 65 years or more compared to volunteers aged 18-45 years, over 24 months duration. It will provide necessary data on the early immunological response to the vaccine and its evolution in quantitative and qualitative terms. This study will allow establishing how aging influences the response to the vaccine and help to adapt the vaccinal plan. For instance it will suggest the necessity of a vaccination booster.

Timeline

Start
2021-02-10
Primary completion
2021-07-01
Completion
2023-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Elasomeran Messenger RNA (mRNA) — —

Indications

No indication recorded.